Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

BACKGROUND: Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease, caused by gain of function mutation in NLRP3 resulting in excess production of interleukin-1 (IL-1). Canakinumab is a human monoclonal antibody against Interleukin-1 beta (IL-1β), licensed for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmi, Abdulkadir A., Wynne, Karen, Cheng, Iek L., Eleftheriou, Despina, Lachmann, Helen J., Hawkins, Philip N., Brogan, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615159/
https://www.ncbi.nlm.nih.gov/pubmed/31287007
http://dx.doi.org/10.1186/s12969-019-0335-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615159/
https://www.ncbi.nlm.nih.gov/pubmed/31287007
http://dx.doi.org/10.1186/s12969-019-0335-4

Ejemplares similares